An analysis of RRAS2 expression in a second array of highly malignant CNS tumors, 57 samples from 19 patients (Table 1b), also revealed R-RAS2 overexpression in grade IV medulloblastomas (n = 18), cerebromas (n = 9), meningioma (n = 11), ependymomas (n = 3) and undifferentiated (n = 15) tumors (Figure 2 and Additional file 1: Figure S1b). Here, RRAS2 is linked to ependymoma.